Please ensure Javascript is enabled for purposes of website accessibility

Here's Why You Can't Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna

By Keith Speights and Danny Vena - Feb 13, 2021 at 7:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's simply not an apples-to-apples comparison.

Johnson & Johnson (JNJ 0.91%) announced late-stage results for its COVID-19 vaccine in late January. The immediate focus was on the vaccine's efficacy, which was markedly lower than efficacy levels reported by Pfizer (PFE -0.15%) and Moderna (MRNA 8.73%) for their COVID-19 vaccines.

In this Motley Fool Live video recorded on Feb. 1, 2021, Motley Fool contributors Keith Speights and Danny Vena discuss one reason why you can't really compare J&J's results with the results reported by Pfizer and Moderna.

Danny Vena: One of the things that I wanted to bring up and maybe you could give us some color on this. I was watching one of the news reports when it first came out, when they announced that Johnson & Johnson was going to be releasing the data on their vaccine.

Dr. John, who's on one of the morning shows, basically, what he said was, when we're looking at a 60 or 70 percent rate versus a 90 something percent rate, it was an apples-to-oranges comparison because the studies had different endpoints. Can you give that a little color because that's something that I'm not sure everybody would understand?

Keith Speights: Yeah. I would have to pull out, Danny, the specific results from these companies to see how their endpoints differ, but there is one notable difference that I'm very aware of. Johnson & Johnson only looked at moderate to severe cases of COVID-19, whereas the Pfizer and Moderna studies looked at all cases.

You might think is that tipping the scale to help Johnson & Johnson come out with a higher efficacy than they otherwise would have? But that's not necessarily the case, because even though they're not looking at the mild cases, there's no guarantee that that would've really materially impacted their efficacy one way or the other. Because there are a lot more milder cases, but there would've been a lot more milder cases probably in the placebo group as well as on the group that took the vaccine.

The comment that it's hard to compare these is exactly right because they're not apples-to-apples, and I think the biggest issue is the introduction of these new variants into the J&J study.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$181.09 (0.91%) $1.63
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.91 (-0.15%) $0.08
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$147.66 (8.73%) $11.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.